Amyloidosis Stocks List

Amyloidosis Stocks Recent News

Date Stock Title
Jul 1 GMAB AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
Jul 1 ALNY Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2
Jun 30 ALNY Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
Jun 29 ALNY Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders
Jun 28 GMAB AbbVie, Genmab blood cancer therapy endorsed in EU
Jun 28 GMAB Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
Jun 27 GMAB Completion of Share Buy-back Program
Jun 27 BBIO BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
Jun 27 ALNY Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Jun 27 ALNY Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Jun 27 GMAB FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
Jun 27 NTLA Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
Jun 27 GMAB Genmab, AbbVie win FDA nod for relapsed follicular lymphoma therapy
Jun 27 NTLA Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
Jun 26 GMAB EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Jun 26 IONS FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Jun 26 NTLA Intellia Therapeutics appoints CFO
Jun 26 NTLA Intellia Therapeutics Announces CFO Transition
Jun 26 NTLA First-of-its-kind Intellia data suggest CRISPR drug could be given more than once
Jun 25 IONS Ionis gains as anti-lipid therapy undergoes FDA priority review
Amyloidosis

Amyloidosis is a disease in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several types with varying symptoms; signs and symptoms may include diarrhea, weight loss, feeling tired, enlargement of the tongue, bleeding, numbness, feeling faint with standing, swelling of the legs, or enlargement of the spleen.There are about 30 different types of amyloidosis, each due to a specific protein misfolding. Some are genetic while others are acquired. They are grouped into localized forms, and systemic ones. The four most common types of systemic amyloidosis are light chain (AL), inflammation (AA), dialysis-related (Aβ2M), and hereditary and old age (ATTR and familial amyloid polyneuropathy).Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach.Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause. AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about 2 per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment, life expectancy is between six months and four years. In the developed world about 1 per 1,000 people die from amyloidosis. Amyloidosis has been described since at least 1639.

Browse All Tags